A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations
This study is the first to investigate the interplay between KRAS mutations and PD-L1 expression in a real-world stage IV lung AC cohort treated with ICIs. Our findings indicate that the p.G12D mutation is associated with an extremely severe disease upon ICI monotherapy. These preliminary results need further validation in larger, prospective cohorts.
Authors
- Samantha Epistolio (ORCID: https://orcid.org/0000-0003-1236-2722)
- J. Pankovics
- Martina Imbimbo (ORCID: https://orcid.org/0000-0003-2521-7540)
- Francesca Molinari
- Lucia Motta (ORCID: https://orcid.org/0000-0002-0481-754X)
- Milo Frattini (ORCID: https://orcid.org/0000-0003-2334-3412)
- Alexandra Valera
- Patrizia Froesch (ORCID: https://orcid.org/0000-0002-8140-1249)
- Miriam Patella (ORCID: https://orcid.org/0000-0002-7622-9472)
- Luca Giudici
- Baptiste Pedrazzini (ORCID: https://orcid.org/0000-0003-3747-072X)
- Giovanna Schiavone
- Stefania Freguia (ORCID: https://orcid.org/0000-0002-9136-3792)
Institutions
- Ente Ospedaliero Cantonale (CH)
Publication Details
- Journal
- Cancers
- Published
- 2025-12-13
- DOI
- https://doi.org/10.3390/cancers17243980
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00